However, to our surprise, serial BMT experiments indicated that Gdpd3−/− retro-CML-LSK cells isolated from primary recipients showed a marked decrease in disease-initiating capacity in second-round recipients compared to Gdpd3+/+ retro-CML-LSK cells (Fig. 2b). The gene discussed is GDPD3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.